- Home
- HQL vs MNPR Comparison
HQL vs MNPR Comparison
Compare HQL & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | MNPR |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.5M | 403.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HQL | MNPR |
|---|---|---|
| Price | $16.23 | $55.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 109.0K | ★ 172.7K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.55 | $26.06 |
| 52 Week High | $17.80 | $105.00 |
Technical Indicators
Market Signals| Indicator | HQL | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 42.30 |
| Support Level | $15.66 | $50.92 |
| Resistance Level | $17.51 | $61.30 |
| Average True Range (ATR) | 0.31 | 3.58 |
| MACD | -0.00 | 0.40 |
| Stochastic Oscillator | 42.46 | 32.19 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.